Sponsor content
213 result(s) found, displaying 51 to 60
-
Prescription medicine decision summaryTGA decision: Gavreto (pralsetinib) is provisionally approved to treat adults with advanced or metastatic rearranged during transfection- fusion positive thyroid cancer.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Roche Products Pty Ltd - Self-care monitoring web-based application software.
-
Prescription medicine registrationActive ingredients: pralsetinib.
-
Prescription medicine registrationActive ingredients: pralsetinib.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ACTEMRA SC tocilizumab (rch) 162 mg/0.9 mL solution for injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ACTEMRA SC tocilizumab (rch) 162 mg/0.9 mL solution for injection pre-filled pen ACTPen Autoinjector.
-
Prescription medicine registrationActive ingredients: polatuzumab vedotin.
-
Cancellation by sponsorRequested by Roche Products Pty Ltd
-
Cancellation by sponsorRequested by Roche Products Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PHESGO SC pertuzumab (rch) 600 mg and trastuzumab (rch) 600mg in 10mL solution for injection, vials.